VNRX vs. ACHV, TKNO, ABIO, ICCC, AWH, OCX, CDIO, TRIB, BMRA, and MYMD
Should you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Achieve Life Sciences (ACHV), Alpha Teknova (TKNO), ARCA biopharma (ABIO), ImmuCell (ICCC), Aspira Women's Health (AWH), OncoCyte (OCX), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Biomerica (BMRA), and MyMD Pharmaceuticals (MYMD). These companies are all part of the "diagnostic substances" industry.
VolitionRx (NYSE:VNRX) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk.
VolitionRx has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.
In the previous week, Achieve Life Sciences had 4 more articles in the media than VolitionRx. MarketBeat recorded 6 mentions for Achieve Life Sciences and 2 mentions for VolitionRx. Achieve Life Sciences' average media sentiment score of 0.84 beat VolitionRx's score of 0.00 indicating that Achieve Life Sciences is being referred to more favorably in the news media.
Achieve Life Sciences received 326 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 70.21% of users gave Achieve Life Sciences an outperform vote while only 26.67% of users gave VolitionRx an outperform vote.
VolitionRx presently has a consensus price target of $2.50, suggesting a potential upside of 267.00%. Achieve Life Sciences has a consensus price target of $14.00, suggesting a potential upside of 164.15%. Given VolitionRx's higher possible upside, equities research analysts plainly believe VolitionRx is more favorable than Achieve Life Sciences.
Achieve Life Sciences has lower revenue, but higher earnings than VolitionRx. Achieve Life Sciences is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.
Achieve Life Sciences has a net margin of 0.00% compared to VolitionRx's net margin of -4,379.67%. VolitionRx's return on equity of 0.00% beat Achieve Life Sciences' return on equity.
8.1% of VolitionRx shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 12.8% of VolitionRx shares are owned by company insiders. Comparatively, 2.0% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Achieve Life Sciences beats VolitionRx on 9 of the 15 factors compared between the two stocks.
Get VolitionRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VolitionRx Competitors List
Related Companies and Tools
